Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Energy & metal in favour today
Thu, 7 Aug 01:30 pm

Indian share markets continued to trade on a weak note in the post-noon trading session. Barring energy and metal, all the sectoral indices are trading in the red with IT and pharma stocks being the biggest losers.

BSE-Sensex is down 96 points and NSE-Nifty is trading 22 points down. BSE Mid Cap is trading 0.5% down and BSE Small Cap index is trading up by 0.4%. The rupee is trading at 61.48 to the US dollar.

Majority of the cement stocks are trading in the red with J K Lakshmi Cement and Heidelberg Cement being the major losers whereas ACC and Ambuja Cement are among the few stocks trading in the green. As per a leading financial daily, Ultratech Cement is contemplating capital spends of Rs 37.9 bn in FY15. Under its capital expenditure plans, the company wants to add 2.9 million tonnes capacity with supporting grinding units and waste heat recovery in its subsidiary Aditya Cement Works in Rajasthan. Additionally, the company will also invest in modernizing its facility at its jetty in Gujarat. The company has earmarked capital investments of Rs 30.5 bn in FY16 and Rs 2 bn in FY17. Ultratech expects its installed capacity to rise from the present 62 million tonnes to 70 million tonnes by early next year. As per the company, its turnover is expected to reach Rs 250 bn in FY15 from Rs 200.7 bn registered in FY14. Ultratech Cement's stock is currently trading up by 1%.

Majority of the domestic pharma stocks are trading negative with J B Chemicals and Indoco Remedies posting maximum losses. As per a leading financial daily, Cadila Healthcare's listed subsidiary Zydus Cadila has received approval from US Food and Drug Administration (USFDA) to market potassium citrate extended-release tablets in the 5mEq, 10mEq and 15mEq strengths. These tablets are used in the prevention of kidney stones. As per IMS data, the estimated sales for potassium citrate ER tablets is $ 131.7 m. Cadila Healthcare presently has 94 approvals and has filed 239 abbreviated new drug applications so far. Cadila Healthcare's stock is trading up by 0.5%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Energy & metal in favour today". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms